Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Myriad Genetics Inc (MYGN)

Myriad Genetics Inc (MYGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,216,228
  • Shares Outstanding, K 91,035
  • Annual Sales, $ 753,200 K
  • Annual Income, $ -263,300 K
  • EBIT $ -102 M
  • EBITDA $ -40 M
  • 60-Month Beta 1.87
  • Price/Sales 1.59
  • Price/Cash Flow N/A
  • Price/Book 1.63

Options Overview Details

View History
  • Implied Volatility 95.96% ( -6.75%)
  • Historical Volatility 42.45%
  • IV Percentile 99%
  • IV Rank 92.32%
  • IV High 102.93% on 12/18/24
  • IV Low 12.10% on 06/03/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 470
  • Volume Avg (30-Day) 89
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 2,743
  • Open Int (30-Day) 2,191

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.07
  • Number of Estimates 6
  • High Estimate -0.06
  • Low Estimate -0.10
  • Prior Year -0.07
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.87 +3.81%
on 12/19/24
16.83 -20.62%
on 12/04/24
-1.94 (-12.68%)
since 11/20/24
3-Month
12.87 +3.81%
on 12/19/24
27.73 -51.82%
on 09/23/24
-14.28 (-51.66%)
since 09/20/24
52-Week
12.87 +3.81%
on 12/19/24
29.30 -54.40%
on 09/18/24
-6.96 (-34.25%)
since 12/20/23

Most Recent Stories

More News
MYGN Stock Might Gain From the New Recognition of RiskScore Study

Myriad Genetics, Inc.’s MYGN MyRisk Hereditary Cancer Test with RiskScore study has been named as one of its top 10 significant advances in genomic medicine by the American Journal of Human Genetics....

MYGN : 13.36 (+1.44%)
PEN : 242.54 (-0.40%)
PAHC : 21.69 (-0.55%)
HAE : 75.44 (-1.90%)
Myriad Genetics' MyRisk® Hereditary Cancer Test with RiskScore® Recognized as Top Advance in Genomic Medicine

Myriad Genetics' MyRisk® Hereditary Cancer Test with RiskScore® was recognized as a significant advance in genomic medicine.Quiver AI SummaryMyriad Genetics, Inc. announced that its MyRisk® Hereditary...

MYGN : 13.36 (+1.44%)
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics

MYGN : 13.36 (+1.44%)
Myriad Genetics Engages with UnitedHealthcare on Access to GeneSight Test Following Policy Update

Myriad Genetics updates on discussions with UnitedHealthcare regarding access to GeneSight test following policy changes effective January 2025.Quiver AI SummaryMyriad Genetics, Inc. has provided an update...

MYGN : 13.36 (+1.44%)
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing

MYGN : 13.36 (+1.44%)
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member

MYGN : 13.36 (+1.44%)
New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain?

Myriad Genetics, Inc.’s MYGN Prolaris prostate cancer prognostic test has been reinforced as an ‘Advanced Tool’ by the National Comprehensive Cancer Network (“NCCN”) in the fight against prostate...

MYGN : 13.36 (+1.44%)
PEN : 242.54 (-0.40%)
PAHC : 21.69 (-0.55%)
HAE : 75.44 (-1.90%)
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines

MYGN : 13.36 (+1.44%)
Myriad Genetics to Present New Breast Cancer Risk Assessment Data at 2024 San Antonio Breast Cancer Symposium

Myriad Genetics will present new breast cancer risk assessment data and MRD assay findings at the 2024 SABCS.Quiver AI SummaryMyriad Genetics, Inc. announced that it will present new research at the 2024...

MYGN : 13.36 (+1.44%)
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium

MYGN : 13.36 (+1.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Myriad Genetics employs a number of proprietary technologies to target the genetic basis of human diseases and the role these genes might play in the onset, progression and treatment of the respective diseases. The company has more than 10 proprietary molecular diagnostic products in market. It has made...

See More

Key Turning Points

3rd Resistance Point 14.12
2nd Resistance Point 13.84
1st Resistance Point 13.60
Last Price 13.36
1st Support Level 13.08
2nd Support Level 12.80
3rd Support Level 12.56

See More

52-Week High 29.30
Fibonacci 61.8% 23.02
Fibonacci 50% 21.08
Fibonacci 38.2% 19.15
Last Price 13.36
52-Week Low 12.87

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar